1 Ashley Road
Altrincham WA14 2DT
44 203 9206789
Full-time employees: 82
|Dr. Saurabh Saha M.D., Ph.D.||CEO & Director||957.67k||N/A||1977|
|Dr. Gregory M. Weinhoff M.B.A., M.D., MBA||Principal Accounting Officer & CFO||655k||N/A||1971|
|Dr. David M. Chao Ph.D.||Chief Admin. Officer||655k||N/A||1968|
|Ms. Kristen K. Sheppard Esq., J.D.||Sr. VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Iqbal J. Hussain L.L.B.||Gen. Counsel, Chief Compliance Officer & Corp. Sec.||N/A||N/A||1981|
|Ms. Karen M. Anderson||Chief People Officer||N/A||N/A||1968|
|Dr. Antoine Yver M.D., M.Sc., MSc||Exec. VP & Chairman of Devel.||N/A||N/A||1958|
|Ms. Tia L. Bush||Chief Quality Officer||N/A||N/A||1971|
|Dr. David John Grainger Ph.D.||Chief Innovation Officer||N/A||N/A||1969|
|Dr. Harris L. Rotman Ph.D.||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Centessa Pharmaceuticals plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.